Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and...
insider buy and new info is coming out. SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it will present the first data from its preclinical synthetic lethality pipeline at the American Association for Cancer Research...
Huge Insider buys. CALA dropped because they discontinued a clinical trail. The insiders obviously must know something we don't or else they wouldn't buy such a huge amount with their own money. I'll stay long with a stop at a close below .81
I expect the KEAPSAKE PH2 data to be good, which should take the stock to 12+ sp in coming months. Data is expected this Q. They have decent amount of cash to fund their trials into late 2H, 2022.
DOUBLE BOTTOM PATTERN, BULLISH DIVERGENCE. WE WILL SEE UPSIDE SOON. ALSO, THE GAP NEEDS TO BE FILLED (MINIMUM 100% PROFIT FROM CURRENT PRICE 2.01)
Wedge breakout + Consolidation Demand Zone confirmation Breakaway Gap OBV> OBV34 WR crossed -80 Entry 2 Stop 1.8 Target 3.6 Risk management is much more important than a good entry point. The max Risk of each plan should be less than 1% of an account. I am not a PRO trader. I trade option to test my trading plan with small cost. I created some tradingview...
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an...
we have a shark pattern on the 2nd wave with a reversal point of $2.23 and on $2.1 C-1-2 could form the cypher pattern. so we have a reversal PRZ with two patterns and since the target of both two patterns is between $11 and $11.7 also we have a target PRZ. the candle of this week could be a beautiful reversal green hammer.
Scenario 1 is more likely than Scenario 2
after 5 or 6 could lift off and the lowest price could see is 2.5
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an...
NASDAQ:CALA - Cup and handle - MACD sloping up - Buy price @ $ 5.01 - 1st target @ $ 5.73 - Stop loss @ $ 4.02
This is a Bullish indicator signaling CALA's price could rise from here. Traders may explore going long the stock or buying call options. I identified 50 similar cases where CALA's MACD histogram became positive, and 44 of them led to successful outcomes. Odds of Success: 88%.
Still indicates that the current trend will persist and may bounce on the trend-line I've drawn based on the weekly charts. The StochRSI is notably showing some weakness and including the MACD, ADX and DI. In the weekly chart it appears that there is a channel forming.